Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis

Active rheumatoid arthritis (RA) is associated with increased cardiovascular risk and impaired function of high-density lipoprotein (HDL). Previous work suggests that HDL may become dysfunctional through oxidative modifications within the RA joint. The current work evaluates an association of synovi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology international 2023-06, Vol.43 (6), p.1041-1053
Hauptverfasser: Charles-Schoeman, Christina, Wang, Jennifer, Shahbazian, Ani, Wilhalme, Holly, Brook, Jenny, Kaeley, Gurjit S., Oganesian, Buzand, Ben-Artzi, Ami, Elashoff, David A., Ranganath, Veena K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1053
container_issue 6
container_start_page 1041
container_title Rheumatology international
container_volume 43
creator Charles-Schoeman, Christina
Wang, Jennifer
Shahbazian, Ani
Wilhalme, Holly
Brook, Jenny
Kaeley, Gurjit S.
Oganesian, Buzand
Ben-Artzi, Ami
Elashoff, David A.
Ranganath, Veena K.
description Active rheumatoid arthritis (RA) is associated with increased cardiovascular risk and impaired function of high-density lipoprotein (HDL). Previous work suggests that HDL may become dysfunctional through oxidative modifications within the RA joint. The current work evaluates an association of synovial power doppler ultrasound signal (PDUS) with HDL function and structure. Two open-label clinical therapeutic studies using PDUS as a disease outcome measure were included in this analysis, including a 12-month trial of subcutaneous abatacept in 24 RA patients and a 6-month trial of IV tocilizumab in 46 RA patients. Laboratory assays included assessments of HDL function and structure, HDL and total cholesterol levels, and a cytokine/chemokine panel. Patients with the highest baseline PDUS scores in both clinical studies, had worse HDL function, including suppression of paraoxonase 1 (PON1) activity as well as lower HDL-C levels. Associations between other disease assessments (DAS28 and CDAI) and HDL function/structure were noted but were generally of lesser magnitude and consistency than PDUS across the HDL profile. Treatment with tocilizumab for 6 months was associated with increases in cholesterol levels and improvements in the HDL function profile, which correlated with greater decreases in PDUS scores. Similar trends were noted following treatment with abatacept for 3 months. Higher baseline PDUS scores identified patients with worse HDL function. This data supports previous work suggesting a direct association of joint inflammation with abnormal HDL function.
doi_str_mv 10.1007/s00296-023-05285-7
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10125943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2780070023</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-877820929b6a023c15994d912d266dccc3e0b63a0f5ce3e9f95811b32434348d3</originalsourceid><addsrcrecordid>eNp9kctu1TAQhq2KqpdTXoAFssSGTVpfEl9WCBVKkY5EF63EznJs5xxXiR1spxVvX5dTSmGBvBjL883vmfkBeIPRKUaIn2WEiGQNIrRBHRFdw_fAEW4pbzBD31-9uB-C45xvEcKcMXQADikTREjSHQF7Fe9dgjbO81jjMpakc1yChdlvgh7hnJz1pmSo-xDTVF8uP63hsARTfAzQBzjr4l2oxL0vW5i2bpl0id5Cnco2-eLzCdgf9Jjd66e4AjcXn6_PL5v1ty9fzz-uG9MSVhrBuSBIEtkzXYcyuJOytRITSxizxhjqUM-oRkNnHHVykJ3AuKekpfUIS1fgw053XvrJWVO7SnpUc_KTTj9V1F79nQl-qzbxTmGESSdbWhXePymk-GNxuajJZ-PGUQcXl6wIF3Xzde-P6Lt_0Nu4pLqySonqB5eyYitAdpRJMefkhuduMFKPLqqdi6qy6peLiteity_neC75bVsF6A7INRU2Lv35-z-yD-DcqWY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2805279902</pqid></control><display><type>article</type><title>Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Charles-Schoeman, Christina ; Wang, Jennifer ; Shahbazian, Ani ; Wilhalme, Holly ; Brook, Jenny ; Kaeley, Gurjit S. ; Oganesian, Buzand ; Ben-Artzi, Ami ; Elashoff, David A. ; Ranganath, Veena K.</creator><creatorcontrib>Charles-Schoeman, Christina ; Wang, Jennifer ; Shahbazian, Ani ; Wilhalme, Holly ; Brook, Jenny ; Kaeley, Gurjit S. ; Oganesian, Buzand ; Ben-Artzi, Ami ; Elashoff, David A. ; Ranganath, Veena K.</creatorcontrib><description>Active rheumatoid arthritis (RA) is associated with increased cardiovascular risk and impaired function of high-density lipoprotein (HDL). Previous work suggests that HDL may become dysfunctional through oxidative modifications within the RA joint. The current work evaluates an association of synovial power doppler ultrasound signal (PDUS) with HDL function and structure. Two open-label clinical therapeutic studies using PDUS as a disease outcome measure were included in this analysis, including a 12-month trial of subcutaneous abatacept in 24 RA patients and a 6-month trial of IV tocilizumab in 46 RA patients. Laboratory assays included assessments of HDL function and structure, HDL and total cholesterol levels, and a cytokine/chemokine panel. Patients with the highest baseline PDUS scores in both clinical studies, had worse HDL function, including suppression of paraoxonase 1 (PON1) activity as well as lower HDL-C levels. Associations between other disease assessments (DAS28 and CDAI) and HDL function/structure were noted but were generally of lesser magnitude and consistency than PDUS across the HDL profile. Treatment with tocilizumab for 6 months was associated with increases in cholesterol levels and improvements in the HDL function profile, which correlated with greater decreases in PDUS scores. Similar trends were noted following treatment with abatacept for 3 months. Higher baseline PDUS scores identified patients with worse HDL function. This data supports previous work suggesting a direct association of joint inflammation with abnormal HDL function.</description><identifier>ISSN: 1437-160X</identifier><identifier>ISSN: 0172-8172</identifier><identifier>EISSN: 1437-160X</identifier><identifier>DOI: 10.1007/s00296-023-05285-7</identifier><identifier>PMID: 36828925</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Abatacept - therapeutic use ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Aryldialkylphosphatase - therapeutic use ; Cholesterol ; Humans ; Lipoproteins, HDL ; Medicine ; Medicine &amp; Public Health ; NCT ; NCT01299961 ; NCT01717859 ; Observational Research ; Rheumatoid arthritis ; Rheumatology ; Ultrasonic imaging ; Ultrasonography, Doppler</subject><ispartof>Rheumatology international, 2023-06, Vol.43 (6), p.1041-1053</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c426t-877820929b6a023c15994d912d266dccc3e0b63a0f5ce3e9f95811b32434348d3</cites><orcidid>0000-0001-5705-1042 ; 0000-0003-1335-3131 ; 0000-0002-5865-8580 ; 0000-0003-3417-9478 ; 0000-0002-1768-7019 ; 0000-0002-8434-6548</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00296-023-05285-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00296-023-05285-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36828925$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Charles-Schoeman, Christina</creatorcontrib><creatorcontrib>Wang, Jennifer</creatorcontrib><creatorcontrib>Shahbazian, Ani</creatorcontrib><creatorcontrib>Wilhalme, Holly</creatorcontrib><creatorcontrib>Brook, Jenny</creatorcontrib><creatorcontrib>Kaeley, Gurjit S.</creatorcontrib><creatorcontrib>Oganesian, Buzand</creatorcontrib><creatorcontrib>Ben-Artzi, Ami</creatorcontrib><creatorcontrib>Elashoff, David A.</creatorcontrib><creatorcontrib>Ranganath, Veena K.</creatorcontrib><title>Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis</title><title>Rheumatology international</title><addtitle>Rheumatol Int</addtitle><addtitle>Rheumatol Int</addtitle><description>Active rheumatoid arthritis (RA) is associated with increased cardiovascular risk and impaired function of high-density lipoprotein (HDL). Previous work suggests that HDL may become dysfunctional through oxidative modifications within the RA joint. The current work evaluates an association of synovial power doppler ultrasound signal (PDUS) with HDL function and structure. Two open-label clinical therapeutic studies using PDUS as a disease outcome measure were included in this analysis, including a 12-month trial of subcutaneous abatacept in 24 RA patients and a 6-month trial of IV tocilizumab in 46 RA patients. Laboratory assays included assessments of HDL function and structure, HDL and total cholesterol levels, and a cytokine/chemokine panel. Patients with the highest baseline PDUS scores in both clinical studies, had worse HDL function, including suppression of paraoxonase 1 (PON1) activity as well as lower HDL-C levels. Associations between other disease assessments (DAS28 and CDAI) and HDL function/structure were noted but were generally of lesser magnitude and consistency than PDUS across the HDL profile. Treatment with tocilizumab for 6 months was associated with increases in cholesterol levels and improvements in the HDL function profile, which correlated with greater decreases in PDUS scores. Similar trends were noted following treatment with abatacept for 3 months. Higher baseline PDUS scores identified patients with worse HDL function. This data supports previous work suggesting a direct association of joint inflammation with abnormal HDL function.</description><subject>Abatacept - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Aryldialkylphosphatase - therapeutic use</subject><subject>Cholesterol</subject><subject>Humans</subject><subject>Lipoproteins, HDL</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>NCT</subject><subject>NCT01299961</subject><subject>NCT01717859</subject><subject>Observational Research</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><subject>Ultrasonic imaging</subject><subject>Ultrasonography, Doppler</subject><issn>1437-160X</issn><issn>0172-8172</issn><issn>1437-160X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kctu1TAQhq2KqpdTXoAFssSGTVpfEl9WCBVKkY5EF63EznJs5xxXiR1spxVvX5dTSmGBvBjL883vmfkBeIPRKUaIn2WEiGQNIrRBHRFdw_fAEW4pbzBD31-9uB-C45xvEcKcMXQADikTREjSHQF7Fe9dgjbO81jjMpakc1yChdlvgh7hnJz1pmSo-xDTVF8uP63hsARTfAzQBzjr4l2oxL0vW5i2bpl0id5Cnco2-eLzCdgf9Jjd66e4AjcXn6_PL5v1ty9fzz-uG9MSVhrBuSBIEtkzXYcyuJOytRITSxizxhjqUM-oRkNnHHVykJ3AuKekpfUIS1fgw053XvrJWVO7SnpUc_KTTj9V1F79nQl-qzbxTmGESSdbWhXePymk-GNxuajJZ-PGUQcXl6wIF3Xzde-P6Lt_0Nu4pLqySonqB5eyYitAdpRJMefkhuduMFKPLqqdi6qy6peLiteity_neC75bVsF6A7INRU2Lv35-z-yD-DcqWY</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Charles-Schoeman, Christina</creator><creator>Wang, Jennifer</creator><creator>Shahbazian, Ani</creator><creator>Wilhalme, Holly</creator><creator>Brook, Jenny</creator><creator>Kaeley, Gurjit S.</creator><creator>Oganesian, Buzand</creator><creator>Ben-Artzi, Ami</creator><creator>Elashoff, David A.</creator><creator>Ranganath, Veena K.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5705-1042</orcidid><orcidid>https://orcid.org/0000-0003-1335-3131</orcidid><orcidid>https://orcid.org/0000-0002-5865-8580</orcidid><orcidid>https://orcid.org/0000-0003-3417-9478</orcidid><orcidid>https://orcid.org/0000-0002-1768-7019</orcidid><orcidid>https://orcid.org/0000-0002-8434-6548</orcidid></search><sort><creationdate>20230601</creationdate><title>Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis</title><author>Charles-Schoeman, Christina ; Wang, Jennifer ; Shahbazian, Ani ; Wilhalme, Holly ; Brook, Jenny ; Kaeley, Gurjit S. ; Oganesian, Buzand ; Ben-Artzi, Ami ; Elashoff, David A. ; Ranganath, Veena K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-877820929b6a023c15994d912d266dccc3e0b63a0f5ce3e9f95811b32434348d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abatacept - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Aryldialkylphosphatase - therapeutic use</topic><topic>Cholesterol</topic><topic>Humans</topic><topic>Lipoproteins, HDL</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>NCT</topic><topic>NCT01299961</topic><topic>NCT01717859</topic><topic>Observational Research</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><topic>Ultrasonic imaging</topic><topic>Ultrasonography, Doppler</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Charles-Schoeman, Christina</creatorcontrib><creatorcontrib>Wang, Jennifer</creatorcontrib><creatorcontrib>Shahbazian, Ani</creatorcontrib><creatorcontrib>Wilhalme, Holly</creatorcontrib><creatorcontrib>Brook, Jenny</creatorcontrib><creatorcontrib>Kaeley, Gurjit S.</creatorcontrib><creatorcontrib>Oganesian, Buzand</creatorcontrib><creatorcontrib>Ben-Artzi, Ami</creatorcontrib><creatorcontrib>Elashoff, David A.</creatorcontrib><creatorcontrib>Ranganath, Veena K.</creatorcontrib><collection>Springer_OA刊</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Rheumatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Charles-Schoeman, Christina</au><au>Wang, Jennifer</au><au>Shahbazian, Ani</au><au>Wilhalme, Holly</au><au>Brook, Jenny</au><au>Kaeley, Gurjit S.</au><au>Oganesian, Buzand</au><au>Ben-Artzi, Ami</au><au>Elashoff, David A.</au><au>Ranganath, Veena K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis</atitle><jtitle>Rheumatology international</jtitle><stitle>Rheumatol Int</stitle><addtitle>Rheumatol Int</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>43</volume><issue>6</issue><spage>1041</spage><epage>1053</epage><pages>1041-1053</pages><issn>1437-160X</issn><issn>0172-8172</issn><eissn>1437-160X</eissn><abstract>Active rheumatoid arthritis (RA) is associated with increased cardiovascular risk and impaired function of high-density lipoprotein (HDL). Previous work suggests that HDL may become dysfunctional through oxidative modifications within the RA joint. The current work evaluates an association of synovial power doppler ultrasound signal (PDUS) with HDL function and structure. Two open-label clinical therapeutic studies using PDUS as a disease outcome measure were included in this analysis, including a 12-month trial of subcutaneous abatacept in 24 RA patients and a 6-month trial of IV tocilizumab in 46 RA patients. Laboratory assays included assessments of HDL function and structure, HDL and total cholesterol levels, and a cytokine/chemokine panel. Patients with the highest baseline PDUS scores in both clinical studies, had worse HDL function, including suppression of paraoxonase 1 (PON1) activity as well as lower HDL-C levels. Associations between other disease assessments (DAS28 and CDAI) and HDL function/structure were noted but were generally of lesser magnitude and consistency than PDUS across the HDL profile. Treatment with tocilizumab for 6 months was associated with increases in cholesterol levels and improvements in the HDL function profile, which correlated with greater decreases in PDUS scores. Similar trends were noted following treatment with abatacept for 3 months. Higher baseline PDUS scores identified patients with worse HDL function. This data supports previous work suggesting a direct association of joint inflammation with abnormal HDL function.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>36828925</pmid><doi>10.1007/s00296-023-05285-7</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-5705-1042</orcidid><orcidid>https://orcid.org/0000-0003-1335-3131</orcidid><orcidid>https://orcid.org/0000-0002-5865-8580</orcidid><orcidid>https://orcid.org/0000-0003-3417-9478</orcidid><orcidid>https://orcid.org/0000-0002-1768-7019</orcidid><orcidid>https://orcid.org/0000-0002-8434-6548</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1437-160X
ispartof Rheumatology international, 2023-06, Vol.43 (6), p.1041-1053
issn 1437-160X
0172-8172
1437-160X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10125943
source MEDLINE; SpringerLink (Online service)
subjects Abatacept - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Aryldialkylphosphatase - therapeutic use
Cholesterol
Humans
Lipoproteins, HDL
Medicine
Medicine & Public Health
NCT
NCT01299961
NCT01717859
Observational Research
Rheumatoid arthritis
Rheumatology
Ultrasonic imaging
Ultrasonography, Doppler
title Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A31%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Power%20doppler%20ultrasound%20signal%20predicts%20abnormal%20HDL%20function%20in%20patients%20with%20rheumatoid%20arthritis&rft.jtitle=Rheumatology%20international&rft.au=Charles-Schoeman,%20Christina&rft.date=2023-06-01&rft.volume=43&rft.issue=6&rft.spage=1041&rft.epage=1053&rft.pages=1041-1053&rft.issn=1437-160X&rft.eissn=1437-160X&rft_id=info:doi/10.1007/s00296-023-05285-7&rft_dat=%3Cproquest_pubme%3E2780070023%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2805279902&rft_id=info:pmid/36828925&rfr_iscdi=true